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Influenza Season and ARDS after Cardiac Surgery
To the Editor: A number of concurrent risk 
factors are associated with development of the 
acute respiratory distress syndrome (ARDS). One 
such risk factor might be asymptomatic respira-
tory viral infection — for example, influenza — 
which could prime the lungs for ARDS in pa-
tients with another overt risk factor. Patients 
who undergo cardiac surgery could potentially 
carry these viruses yet have no clinical signs or 
symptoms.1
In a retrospective observational cohort of 
2013 patients who underwent cardiac surgery 
between January 2009 and January 2012, we 
compared the incidence of ARDS after surgery 
during influenza seasons (typically from Decem-
ber through February, when influenza is most 
likely to be isolated from body fluids)2 with the 
incidence of ARDS after surgery during seasons 
with few, if any, influenza cases (baseline sea-
sons). None of the patients in our study who 
underwent elective surgery had noted preopera-
tive respiratory symptoms or fever in any of the 
seasons examined. In our analysis, the primary 
outcome was development of ARDS within 7 days 
after surgery, assessed with the use of the Berlin 
criteria.3 We obtained data regarding chest radio-
graphs and the ratio between the partial pressure 
of arterial oxygen and the fraction of inspired 
oxygen (Pao2:Fio2) through manual chart review. 
The secondary outcome measures were duration 
of mechanical ventilation, length of stay in the 
intensive care unit (ICU), and mortality. We 
added other, well-known risk factors in our multi-
variable model (details are provided in the Sup-
plementary Appendix, available with the full text 
of this letter at NEJM.org).
Among the 740 patients who were admitted 
to the ICU after cardiac surgery during baseline 
periods, ARDS developed in 38 (5.1%). In the 
periods between baseline and influenza seasons, 
ARDS developed in 55 of 984 patients (5.6%), 
and during influenza seasons, ARDS developed 
in 26 of 289 patients (9.0%). All cases of ARDS 
occurred within the first 26 hours after surgery. 
In our models, cardiac surgery during influenza 
seasons versus baseline seasons was an indepen-
dent risk factor for development of ARDS (odds 
ratio, 1.85; 95% confidence interval, 1.06 to 3.23) 
(Table 1). Furthermore, the duration of mechan-
ical ventilation was significantly longer in the 
influenza seasons than in baseline seasons.
In another study, involving children, no differ-
ences in postoperative length of hospital stay 
were found among seasons.4 In addition to the 
use of a different end point that did not include 
ARDS, the definition of respiratory-virus season 
in that study was not based on viral identifica-
tion, and the sample size was much smaller, 
which made the study underpowered to reveal 
the association that we identified. For the rela-
tionship that we found between influenza sea-
son and ARDS after cardiac surgery to be of 
clinical value, research is needed to determine 
whether perioperative strategies aimed at pre-
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venting, detecting, or treating subclinical influ-
enza might reduce the number of patients in 
whom ARDS develops.
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Preventive Therapies for Chronic Migraine
To the Editor: In the November 30 issue, two 
groups of researchers report the results of phase 3 
clinical trials of drugs for the prevention of mi-
graine. Silberstein et al.1 describe the efficacy of 
fremanezumab, a monoclonal antibody targeting 
calcitonin gene–related peptide (CGRP), and 
Goadsby et al.2 describe the efficacy of the anti-
CGRP receptor erenumab. With respect to the ef-
fects of these two drugs, we note that CGRP is a 
potent endogenous vasodilator. Our group has 
been investigating the role of CGRP in vascular 
tone in experimental models. CGRP seems to 
play a larger role in altering vascular tone in rats 
with hypertension than in those with normoten-
sion.3,4 However, in the clinical trial, no changes 
in hemodynamics were reported with fremanezu-
mab, although one episode of hypertensive crisis 
was described. Patients who were treated with 
erenumab were reported to have a slightly lower 
rate of hypertension than those who received 
placebo. We ask the authors for their view on 
the lack of substantial effect on blood pressure 
that was associated with the blockade of CGRP 
or its receptor. Also, do the authors have data 
to determine whether there were differences in 
treatment efficacy or safety between patients 
with hypertension and those without hyper-
tension?
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Outcome Value (95% CI) P Value
Odds ratio for ARDS in influenza seasons vs. baseline seasons 1.85 (1.06 to 3.23) 0.03
Absolute difference in duration of mechanical ventilation between  
influenza seasons and baseline seasons — hr
22.64 (0.47 to 44.81) 0.05
Absolute difference in length of stay in ICU between influenza  
seasons and baseline seasons — hr
21.08 (−1.42 to 43.58) 0.07
Odds ratio for death in the ICU in influenza seasons vs. baseline  
seasons
1.57 (0.58 to 4.24) 0.37
*  Data are primary and secondary outcome measures from multivariable modeling in which age, sex, body‑mass index, 
EuroSCORE (a preoperative risk score; scores range from 1 to 99, with higher scores indicating a higher risk of death), 
Acute Physiology and Chronic Health Evaluation (APACHE) IV score (a marker of illness at admission to the intensive 
care unit [ICU]), time in surgery, duration of cardiopulmonary bypass, units of blood products received during surgery, 
and season of surgery were evaluated. ARDS denotes acute respiratory distress syndrome, and CI confidence interval.
Table 1. Primary and Secondary Outcome Measures during Influenza Seasons versus Baseline Seasons.*
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